vs

Side-by-side financial comparison of Bloomin' Brands, Inc. (BLMN) and Revvity (RVTY). Click either name above to swap in a different company.

Bloomin' Brands, Inc. is the larger business by last-quarter revenue ($975.2M vs $772.1M, roughly 1.3× Revvity). Revvity runs the higher net margin — 12.7% vs -1.4%, a 14.1% gap on every dollar of revenue. On growth, Revvity posted the faster year-over-year revenue change (5.9% vs 0.3%). Revvity produced more free cash flow last quarter ($161.8M vs $63.7M). Over the past eight quarters, Revvity's revenue compounded faster (9.0% CAGR vs -4.5%).

Bloomin' Brands, Inc. is a restaurant holding company that owns several American casual dining restaurant chains. The company was established in 1988 in Tampa, Florida, where it is headquartered.

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

BLMN vs RVTY — Head-to-Head

Bigger by revenue
BLMN
BLMN
1.3× larger
BLMN
$975.2M
$772.1M
RVTY
Growing faster (revenue YoY)
RVTY
RVTY
+5.5% gap
RVTY
5.9%
0.3%
BLMN
Higher net margin
RVTY
RVTY
14.1% more per $
RVTY
12.7%
-1.4%
BLMN
More free cash flow
RVTY
RVTY
$98.1M more FCF
RVTY
$161.8M
$63.7M
BLMN
Faster 2-yr revenue CAGR
RVTY
RVTY
Annualised
RVTY
9.0%
-4.5%
BLMN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLMN
BLMN
RVTY
RVTY
Revenue
$975.2M
$772.1M
Net Profit
$-13.5M
$98.4M
Gross Margin
70.2%
Operating Margin
-1.4%
14.5%
Net Margin
-1.4%
12.7%
Revenue YoY
0.3%
5.9%
Net Profit YoY
83.0%
3.9%
EPS (diluted)
$-0.16
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLMN
BLMN
RVTY
RVTY
Q4 25
$975.2M
$772.1M
Q3 25
$928.8M
$698.9M
Q2 25
$1.0B
$720.3M
Q1 25
$1.0B
$664.8M
Q4 24
$972.0M
$729.4M
Q3 24
$910.0M
$684.0M
Q2 24
$999.4M
$691.7M
Q1 24
$1.1B
$649.9M
Net Profit
BLMN
BLMN
RVTY
RVTY
Q4 25
$-13.5M
$98.4M
Q3 25
$-45.9M
$46.7M
Q2 25
$25.4M
$53.9M
Q1 25
$42.2M
$42.2M
Q4 24
$-79.5M
$94.6M
Q3 24
$6.9M
$94.4M
Q2 24
$28.4M
$55.4M
Q1 24
$-83.9M
$26.0M
Gross Margin
BLMN
BLMN
RVTY
RVTY
Q4 25
70.2%
Q3 25
70.4%
53.6%
Q2 25
70.2%
54.5%
Q1 25
70.1%
56.5%
Q4 24
71.6%
Q3 24
71.3%
56.3%
Q2 24
70.5%
55.7%
Q1 24
70.5%
54.6%
Operating Margin
BLMN
BLMN
RVTY
RVTY
Q4 25
-1.4%
14.5%
Q3 25
-3.9%
11.7%
Q2 25
3.0%
12.6%
Q1 25
5.5%
10.9%
Q4 24
1.7%
16.3%
Q3 24
0.9%
14.3%
Q2 24
4.4%
12.4%
Q1 24
6.6%
6.8%
Net Margin
BLMN
BLMN
RVTY
RVTY
Q4 25
-1.4%
12.7%
Q3 25
-4.9%
6.7%
Q2 25
2.5%
7.5%
Q1 25
4.0%
6.4%
Q4 24
-8.2%
13.0%
Q3 24
0.8%
13.8%
Q2 24
2.8%
8.0%
Q1 24
-7.8%
4.0%
EPS (diluted)
BLMN
BLMN
RVTY
RVTY
Q4 25
$-0.16
$0.86
Q3 25
$-0.54
$0.40
Q2 25
$0.30
$0.46
Q1 25
$0.50
$0.35
Q4 24
$-0.93
$0.77
Q3 24
$0.08
$0.77
Q2 24
$0.32
$0.45
Q1 24
$-0.96
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLMN
BLMN
RVTY
RVTY
Cash + ST InvestmentsLiquidity on hand
$59.5M
$919.9M
Total DebtLower is stronger
$787.4M
Stockholders' EquityBook value
$333.6M
$7.3B
Total Assets
$3.2B
$12.2B
Debt / EquityLower = less leverage
2.36×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLMN
BLMN
RVTY
RVTY
Q4 25
$59.5M
$919.9M
Q3 25
$66.5M
$931.4M
Q2 25
$50.3M
$991.8M
Q1 25
$57.7M
$1.1B
Q4 24
$70.1M
$1.2B
Q3 24
$83.6M
$1.2B
Q2 24
$117.9M
$2.0B
Q1 24
$131.7M
$1.7B
Total Debt
BLMN
BLMN
RVTY
RVTY
Q4 25
$787.4M
Q3 25
$962.2M
Q2 25
$917.1M
Q1 25
$917.6M
Q4 24
$1.0B
Q3 24
$1.1B
Q2 24
$1.0B
Q1 24
$951.8M
Stockholders' Equity
BLMN
BLMN
RVTY
RVTY
Q4 25
$333.6M
$7.3B
Q3 25
$344.1M
$7.4B
Q2 25
$397.2M
$7.6B
Q1 25
$380.6M
$7.6B
Q4 24
$135.5M
$7.7B
Q3 24
$242.1M
$7.9B
Q2 24
$286.8M
$7.9B
Q1 24
$302.7M
$7.8B
Total Assets
BLMN
BLMN
RVTY
RVTY
Q4 25
$3.2B
$12.2B
Q3 25
$3.3B
$12.1B
Q2 25
$3.3B
$12.4B
Q1 25
$3.3B
$12.4B
Q4 24
$3.4B
$12.4B
Q3 24
$3.4B
$12.8B
Q2 24
$3.4B
$13.4B
Q1 24
$3.4B
$13.4B
Debt / Equity
BLMN
BLMN
RVTY
RVTY
Q4 25
2.36×
Q3 25
2.80×
Q2 25
2.31×
Q1 25
2.41×
Q4 24
7.58×
Q3 24
4.51×
Q2 24
3.49×
Q1 24
3.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLMN
BLMN
RVTY
RVTY
Operating Cash FlowLast quarter
$119.1M
$182.0M
Free Cash FlowOCF − Capex
$63.7M
$161.8M
FCF MarginFCF / Revenue
6.5%
21.0%
Capex IntensityCapex / Revenue
5.7%
2.6%
Cash ConversionOCF / Net Profit
1.85×
TTM Free Cash FlowTrailing 4 quarters
$96.8M
$509.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLMN
BLMN
RVTY
RVTY
Q4 25
$119.1M
$182.0M
Q3 25
$34.4M
$138.5M
Q2 25
$49.7M
$134.3M
Q1 25
$73.5M
$128.2M
Q4 24
$119.8M
$174.2M
Q3 24
$-7.8M
$147.9M
Q2 24
$42.4M
$158.6M
Q1 24
$73.8M
$147.6M
Free Cash Flow
BLMN
BLMN
RVTY
RVTY
Q4 25
$63.7M
$161.8M
Q3 25
$-5.7M
$120.0M
Q2 25
$11.1M
$115.5M
Q1 25
$27.7M
$112.2M
Q4 24
$66.7M
$149.8M
Q3 24
$-67.3M
$125.6M
Q2 24
$-12.1M
$136.6M
Q1 24
$20.0M
$129.7M
FCF Margin
BLMN
BLMN
RVTY
RVTY
Q4 25
6.5%
21.0%
Q3 25
-0.6%
17.2%
Q2 25
1.1%
16.0%
Q1 25
2.6%
16.9%
Q4 24
6.9%
20.5%
Q3 24
-7.4%
18.4%
Q2 24
-1.2%
19.7%
Q1 24
1.9%
20.0%
Capex Intensity
BLMN
BLMN
RVTY
RVTY
Q4 25
5.7%
2.6%
Q3 25
4.3%
2.6%
Q2 25
3.8%
2.6%
Q1 25
4.4%
2.4%
Q4 24
5.5%
3.4%
Q3 24
6.5%
3.3%
Q2 24
5.5%
3.2%
Q1 24
5.0%
2.7%
Cash Conversion
BLMN
BLMN
RVTY
RVTY
Q4 25
1.85×
Q3 25
2.97×
Q2 25
1.95×
2.49×
Q1 25
1.74×
3.03×
Q4 24
1.84×
Q3 24
-1.13×
1.57×
Q2 24
1.49×
2.87×
Q1 24
5.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLMN
BLMN

Food And Beverage$958.0M98%
Franchiseand Other Revenue$17.2M2%
International Franchise Segment$7.8M1%

RVTY
RVTY

Immunodiagnostics$240.8M31%
Life Sciences$191.4M25%
Reproductive Health$149.3M19%
Segment Operating Income$132.0M17%
Software$62.3M8%

Related Comparisons